Gustavo Viani/sbradioterapia.com.br
Feb 16, 2025, 22:38
Gustavo Viani: Hippocampal-Avoidance PCI: Game-Changer or Cognitive Mirage?
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared an article by Haiyan Zeng, et al. on X:
“Hippocampal-Avoidance PCI: Game-Changer or Cognitive Mirage?
Objective:
- Evaluate the impact of HA-PCI on self-reported cognitive function and metastases risk in SCLC.
Methods:
- Pooled data from two phase III RCTs (NCT01780675 & PREMER).
- Randomized comparison: Standard PCI vs. HA-PCI.
Results:
- No significant cognitive benefit with HA-PCI (p=0.52).
- No increased risk of brain metastases (p=0.9).
- At 4 months, HA-PCI showed cognitive impairment (p*=0.04), but this effect was not sustained over time.
Conclusion:
- HA-PCI is safe but does Not significantly protect cognition.
- Future PCI strategies should explore neuroprotective agents to enhance cognitive outcomes!”
Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials.
Authors: Haiyan Zeng, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 05:05
Feb 20, 2025, 11:19
Feb 20, 2025, 11:13
Feb 20, 2025, 11:08
Feb 20, 2025, 11:00
Feb 20, 2025, 10:52